Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Ekaphop, Sirachainan"'
Autor:
Songporn Oranratnachai, Sasivimol Rattanasiri, Ekaphop Sirachainan, Amarit Tansawet, Nilubol Raunroadroong, Gareth J. McKay, John Attia, Ammarin Thakkinstian
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3046-3053 (2023)
Abstract Background Multikinase inhibitors (MKIs) represent the main treatment options for advanced hepatocellular carcinoma (aHCC). However, accessibility in developing countries is limited. A chemotherapy, Fluorouracil and Oxaliplatin (FOLFOX), off
Externí odkaz:
https://doaj.org/article/8d6555e6533343609bcc614e15de136d
Autor:
Khantong Khiewngam, Songporn Oranratnachai, Kaettipong Kamprerasart, Patratorn Kunakorntham, Pimtip Sanvarinda, Narumol Trachu, Pongput Pimsa, Jirapath Wiwitkeyoonwong, Thanaporn Thamrongjirapat, Thitiya Dejthevaporn, Ekaphop Sirachainan, Thanyanan Reungwetwattana
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundDespite significant benefits of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR-mutated NSCLC, access remains limited in Thailand and elsewhere.MethodsRetrospective analysis of patients
Externí odkaz:
https://doaj.org/article/0a08eba3ebc647689bed9d3a6755ea74
Autor:
Chanchai Charonpongsuntorn, Suebpong Tanasanvimon, Krittiya Korphaisarn, Songwit Payapwattanawong, Teerada Siripoon, Nussara Pakvisal, Jitlada Juengsamarn, Ekkamol Phaibulvatanapong, Jarin Chindaprasirt, Naiyarat Prasongsook, Kittipong Udomdamrongkul, Nuttapong Ngamphaiboon, Ekaphop Sirachainan
Publikováno v:
JCO Global Oncology, Vol , Iss 8 (2022)
PURPOSEAtezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aim
Externí odkaz:
https://doaj.org/article/1e83d097148742f5863ad6c1cc7882ca
Autor:
Nintita Sripaiboonkij Thokanit, Sopit Promchana, Tanapol Thonkamdee, Pornsuda Jitkasikorn, Teerada Siripoon, Nuttapong Ngamphaiboon, Ekaphop Sirachainan
Publikováno v:
Iranian Journal of Public Health, Vol 51, Iss 11 (2022)
Background: In Thailand, data on colorectal cancer (CRC) patient characteristics and overall survival (OS) rates are limited. We aimed to describe the overall 5-year, 10-year survival and to examine factors effecting the survival outcome among patien
Externí odkaz:
https://doaj.org/article/292de022c34f4a0b8bcb7ce062a06abb
Autor:
Chalirmporn Atasilp, Rinradee Lenavat, Natchaya Vanwong, Phichai Chansriwong, Ekaphop Sirachainan, Thanyanan Reungwetwattana, Pimonpan Jinda, Somthawin Aiempradit, Suwannee Sirilerttrakul, Monpat Chamnanphon, Apichaya Puangpetch, Nipaporn Sankuntaw, Patompong Satapornpong, Chonlaphat Sukasem
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe two common methylenetetrahydrofolate reductase (MTHFR) polymorphisms 677G>A and 1298A>C may have been affecting 5-FU toxicity in cancer patients for decades. Drug efficacy has also been shown by previous studies to be affected. In this
Externí odkaz:
https://doaj.org/article/96d3eaa1f34b464da29018c8e91c88dd
Autor:
Anita Archwamety, Nattaya Teeyapun, Teerada Siripoon, Naravat Poungvarin, Suebpong Tanasanvimon, Ekaphop Sirachainan, Charuwan Akewanlop, Krittiya Korphaisarn
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCurrent guidelines recommend anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR Ab) as first-line treatment only in patients with left-sided RAS wild type (RASwt) metastatic colorectal cancer (mCRC). However, there are n
Externí odkaz:
https://doaj.org/article/f93b82fc8322451c8cf7e1084cfcd615
Autor:
Fabio Augusto Barros Schutz, Ekaphop Sirachainan, Shanggar Kuppusamy, Nguyen Thi Thai Hoa, Thitiya Dejthevaporn, Badrulhisham Bahadzor, Vu Quang Toan, Phichai Chansriwong, Adlinda Alip, Nguyen Thi Minh Hue, Napa Parinyanitikul, Ai Lian Tan, Vu Dinh Khanh Hoang, Piyawan Tienchaiananda, Sai Naga Deepak Chinchapattanam, Amit Garg
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Aims: Clinical decision making is challenging in men with metastatic prostate cancer (mPC), as heterogeneity in treatment options and patient characteristics have resulted in multiple scenarios with little or no evidence. The South East Asia Expert P
Externí odkaz:
https://doaj.org/article/b0c04b1a3e17433096b3ca7eae3696de
Autor:
Pimpin, Incharoen, Artit, Jinawath, Lalida, Arsa, Kaettipong, Kamprerasart, Narumol, Trachu, Nanamon, Monnamo, Khantong, Khiewngam, Dittapol, Muntham, Phichai, Chansriwong, Ekaphop, Sirachainan, Thanyanan, Reungwetwattana
Publikováno v:
Cancer Biomarkers. 36:71-82
BACKGROUND: Information on genetic alterations, notably EGFR mutations, is important for guiding non-small-cell lung cancer (NSCLC) treatment. Circulating tumor DNA (ctDNA) analysis represents a less invasive alternative to tissue biopsy for analyzin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d7401f681095139a1b8be63f67d21c6
https://doi.org/10.3233/cbm-220079
https://doi.org/10.3233/cbm-220079
Autor:
Mitsumi Terada, Kenichi Nakamura, Tomohiro Matsuda, Hitomi Sumiyoshi Okuma, Kazuki Sudo, Akhmal Yusof, Marcelo Imasa, Ekaphop Sirachainan, Pham Tuan Anh, Yasuhiro Fujiwara, Noboru Yamamoto, Pei Jye Voon, Kulkanya Chokephaibulkit, Tatsuhiro Shibata, Manami Inoue, Hiroyuki Mano, Tatsunori Shimoi, Virote Sriuranpong, Kan Yonemori, Kazuaki Shimada
Publikováno v:
Japanese Journal of Clinical Oncology.
This report summarizes the presentations and discussions in the first Asian Clinical Trials Network for Cancers (ATLAS) international symposium that was held on 24 April 2022, in Bangkok, Thailand, and hosted by the National Cancer Center Hospital (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86f157840a3ee6b24d40941e05bdbdc9
https://doi.org/10.1093/jjco/hyad033
https://doi.org/10.1093/jjco/hyad033
Autor:
Songporn Oranratnachai, Sasivimol Rattanasiri, Ekaphop Sirachainan, Amarit Tansawet, Nilubol Raunroadroong, Gareth J. McKay, John Attia, Ammarin Thakkinstian
Publikováno v:
Oranratnachai, S, Rattanasiri, S, Sirachainan, E, Tansawet, A, Raunroadroong, N, McKay, G J, Attia, J & Thakkinstian, A 2022, ' Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors ', Cancer Medicine . https://doi.org/10.1002/cam4.5224
BACKGROUND: Multikinase inhibitors (MKIs) represent the main treatment options for advanced hepatocellular carcinoma (aHCC). However, accessibility in developing countries is limited. A chemotherapy, Fluorouracil and Oxaliplatin (FOLFOX), offers a le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::884a16f4e68e21188251aff202b7f4b2
https://pure.qub.ac.uk/en/publications/9983cad8-b4e0-4ab8-87f2-3bf3c07963be
https://pure.qub.ac.uk/en/publications/9983cad8-b4e0-4ab8-87f2-3bf3c07963be
